Several markers of disease progression were followed throughout the open-label extension clinical trial, including the ALSFRS-R, vital capacity, total body weight and body mass index (a measure of obesity). In the absence of placebo control, CytRx chose to compare the open-label clinical trial results with the placebo group of a recently-published clinical trial (Cudkowicz, M.E., et. al., Annals of Neurology 2006 volume 60:22-31) that enrolled patients with very similar characteristics. While difficult to draw definitive conclusions without a concurrent placebo control group, there was an apparent trend toward a slower decline in every disease progression marker in the arimoclomol open-label clinical trial compared with the historical placebo control. In the trial, CytRx observed a decrease in the rate of decline of 21% for ALSFRS-R, 8.0% for vital capacity, 23% for total body weight and 20% for body mass index when compared with that historical control.